Private Company
Funding information not available
Overview
Empirico is a private, clinical-stage biotech leveraging a proprietary, integrated platform that combines human genetics and siRNA technology to discover and develop novel genetic medicines for common diseases with high unmet need. The company has built internal capabilities across the entire drug discovery value chain and has established a strategic partnership with GSK for a clinical-stage respiratory program. With a pipeline of clinical and preclinical programs and a seasoned leadership team, Empirico is positioned to advance a new generation of precision therapeutics.
Technology Platform
Integrated platform combining human genetics-driven computational target discovery with world-class siRNA chemistry and drug development capabilities to create medicines that mimic protective genetic variants.
Opportunities
Risk Factors
Competitive Landscape
Empirico competes with established public RNAi companies like Alnylam and Arrowhead Pharmaceuticals, as well as other genetics-driven biotechs such as Regeneron Genetics Center spin-outs and large pharma internal efforts. Its differentiation lies in the tight integration of its genetics and siRNA platforms from discovery through development.